La Jolla Pharmaceutical Company is a biopharmaceutical company that specializes in the development of life-saving medicines. Its main focus is on creating therapeutics to treat severe illnesses. The company is working on two main treatments: LJPC-501, an angiotensin II potential treatment for catecholamine-resistant hypotension and hepatorenal syndrome, and GCS-100, a galectin-3 inhibitor with the potential to treat chronic kidney disease. La Jolla Pharmaceutical Company is dedicated to improving quality of life for patients worldwide.